Approval · Notice of Compliance 10286 · 2009
CYMBALTA: Notice of Compliance 10286
Issued June 24, 2009
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 10286
- Date
- June 24, 2009
- Company
- Eli Lilly Canada IncToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: for the management of pain associated with fibromyalgia
- Therapeutic class
- Antidepressant / anxiolytic / analgesic
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CYMBALTA | Not yet assigned | — |
Medicinal ingredients
- DULOXETINE HYDROCHLORIDE 30 MG per CAP
- DULOXETINE HYDROCHLORIDE 60 MG per CAP